Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy
Authors:
Open Access
- 15 August 2017
- journal article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 89 (8) , 5-12
Abstract
In current clinical practice, there is no optimal empirical therapy for Helicobacter pylori (H. pylori) infection and there is a progressive decrease in the efficiency of classical eradication therapy (ET) regimens. The variability in the efficiency of ET in a specific patient is largely due to the heterogeneous molecular genetic mechanisms underlying the resistance of the microorganism to the components of the treatment regimens. The basis of the mechanisms for antibiotic resistance in H. pylori is mainly the point mutations in some genes, which determine alterations in the mechanisms of action of drugs, such as clarithromycin (domain V of 23S rRNA), metronidazole (rdxA, frxA), amoxicillin (pbp1A), tetracycline (16S rRNA), and levofloxacin (gyrA). The predictors of resistance to ET are also the CagA-negative status of the microorganism and the presence of the vacA s2 allele. There are a number of host genetic determinants (the CYP2C19 genotype (*1/*1, *1/*17, *17/*17) and the MDR1 3435 T/T genotype (in an Asian population)) that reduce the efficiency of ET, by altering the pharmacokinetics of proton pump inhibitors. In addition, the IL-1β-511 C/C polymorphism that affects gastric acid secretion is a predictor of the inefficiency of ET.Keywords
This publication has 83 references indexed in Scilit:
- Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment of Helicobacter pylori InfectionDigestion, 2013
- Recent Insights into Antibiotic Resistance inHelicobacter pyloriEradicationGastroenterology Research and Practice, 2012
- The benefit of mass eradication ofHelicobacter pyloriinfection: a community-based study of gastric cancer preventionGut, 2012
- Helicobacter pyloritherapy: Present and futureWorld Journal of Gastrointestinal Pharmacology and Therapeutics, 2012
- Mechanisms ofHelicobacter pyloriantibiotic resistance: An updated appraisalWorld Journal of Gastrointestinal Pathophysiology, 2011
- Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori InfectionGastroenterology Clinics of North America, 2010
- Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17British Journal of Clinical Pharmacology, 2010
- Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pyloriJournal of Gastroenterology and Hepatology, 2009
- Helicobacter pylori VacA Disrupts Apical Membrane-Cytoskeletal Interactions in Gastric Parietal CellsJournal of Biological Chemistry, 2008
- Pathogenesis ofHelicobacter pyloriInfectionClinical Microbiology Reviews, 2006